Strides Pharma Science Limited has informed about the Earnings Presentation for the quarter and financial year ended March 31, 2026.
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Strides Pharma reported FY26 revenue of ₹48,587m (up 6.4% YoY) with strong profitability improvement. Gross margins expanded by 310 basis points to 59.7%, while EBITDA grew 15.3% to ₹9,253m with margin at 19%. Operational PAT jumped 50% YoY to ₹5,181m, with EPS at ₹56.2. The board recommended a dividend of ₹5 per share. Ex-US markets drove growth with 21% YoY increase to $254m, offsetting a weaker US flu season. Net debt reduced to ₹13,250m on constant currency basis, improving Net Debt/EBITDA to 1.55x. The company guided for ~$400m US revenue aspiration by FY28.
The strong profitability expansion with 50% PAT growth and improved margins signals effective operating leverage. The dividend and deleveraging indicate financial health, though the US market weakness and geopolitical headwinds warrant monitoring. The stock could see positive reaction given beating operational performance.